First Author: T.Diago SPAIN
Co Author(s): J.M. Tomás C. Vilela M. Diago 0 0 0 0 0 0 0 0 0
Back to previous
Until now, the treatment for hepatitis C virus (HCV) included interferon which occasionally produced adverse effects on the retina. A new era in the treatment for these patients is opened with direct-acting antivirals (DAA). The purpose is to study the action of the new treatment (DAA) for HCV on the retina.
Hospital Universitario de La Ribera. (Alzira, Valencia) (Spain)
Prospective study in which 16 patients with HCV who are going to start treatment with DAA are included. Before the treatment an ophthalmological examination is practised which includes: Visual acuity (VA), funduscopy, optical coherence tomography (OCT), multifocal electroretinogram (mERG). After the end of this treatment the ophthalmological examination is reapetead including VA, funduscopy, OCT and mERG.
Significant statistical differences are not observed in the structural tests and in the functional tests of the retina of these patients.
The treatment for HVC with DDA does not produce structural and functional changes of the retina. These patients do not need a protocolized screening of their retina.